SCHEMBL4989707

SCHEMBL4989707

CC(C)=CCN1C(=O)C=CC1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 11/20 0.46
ALDH1A1 P00352 3/20 0.46
BLM P54132 2/20 0.46
LMNA P02545 2/20 0.46
MAPT P10636 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
GMNN O75496 1/20 0.46
THPO P40225 1/20 0.46
PMP22 Q01453 1/20 0.46
FAAH O00519 4/20 0.41
HPGD P15428 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
WRN Q14191 1/20 0.39
HIF1A Q16665 1/20 0.39
HSP90AA1 P07900 1/20 0.39
TLR9 Q9NR96 1/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
XBP1 P17861 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25420576 0.83 KMT2A (0.48) ALDH1A1MAPTPTGS1
SCHEMBL10743946 0.73 MGLL (0.46) MGLLALDH1A1BLMLMNAMAPT
SCHEMBL4017572 0.71 ALDH1A1 (0.55) ALDH1A1MAPTNPSR1HPGDTP53
SCHEMBL4595331 0.70 MGLL (0.48) MGLLALDH1A1BLMLMNAMAPT
SCHEMBL9181540 0.70 MGLL (0.48) MGLLALDH1A1BLMLMNAMAPT
SCHEMBL6537077 0.70 MGLL (0.48) MGLLALDH1A1BLMLMNAMAPT
SCHEMBL822301 0.70 MGLL (0.42) MGLLALDH1A1BLMLMNAMAPT
SCHEMBL1264929 0.69 ALOX15 (0.49) MGLLALDH1A1BLMLMNAMAPT
SCHEMBL1264927 0.69 ALOX15 (0.49) MGLLALDH1A1BLMLMNAMAPT
SCHEMBL88581 0.69 CASP3 (0.48) MGLLALDH1A1BLMLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2906972-B1 OPTICAL MEMBER COMPRISING A LAMINATED BODY WITH POLYMER LAYER CONTAINING A MALEIMIDE COPOLYMER AND METHOD FOR MANUFACTURING THE SAME CANON KK (JP) 2017-07-05 EP disclosed
US-20170176644-A1 OPTICAL MEMBER AND METHOD FOR MANUFACTURING THE SAME CANON KABUSHIKI KAISHA (JP) 2017-06-22 US disclosed
US-20150316691-A1 OPTICAL MEMBER AND METHOD FOR MANUFACTURING THE SAME CANON KABUSHIKI KAISHA (JP) 2015-11-05 US disclosed
EP-2906972-A2 ANTI-REFLECTIVE FIM COMPRISING AN MALEIMIDE-COPOLYMER BASED INTERMEDIATE LAYER Canon Kabushiki Kaisha (JP) 2015-08-19 EP disclosed
WO-2015080030-A1 OPTICAL MEMBER AND METHOD FOR MANUFACTURING THE SAME CANON KABUSHIKI KAISHA (JP) 2015-06-04 WO disclosed
WO-2014084328-A2 OPTICAL MEMBER AND METHOD FOR MANUFACTURING THE SAME CANON KABUSHIKI KAISHA (JP) 2014-06-05 WO disclosed
US-7368516-B2 Catalyst for trimerization of ethylene and process for trimerizing ethylene using the catalyst TOSOH CORPORATION (JP) 2008-05-06 US disclosed
US-20050187419-A1 Catalyst for trimerization of ethylene and process for trimerizing ethylene using the catalyst TOSOH CORPORATION (JP) 2005-08-25 US disclosed
US-6900152-B2 Catalyst for trimerization of ethylene and process for trimerizing ethylene using the catalyst TOSOH CORPORATION (JP) 2005-05-31 US disclosed
US-20020035029-A1 Catalyst for trimerization of ethylene and process for trimerizing ethylene using the catalyst TOSOH CORPORATION (JP) 2002-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187419-A1 Catalyst for trimerization of ethylene and process for trimerizing ethylene using the catalyst ACMSD, TAF9, ETV6 MGLL 1715/4885ALDH1A1 2843/4885BLM 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.